UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): April 15, 2008
VioQuest
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
|
|
58-1486040
|
| |
|
|
|
|
|
(State
or other jurisdiction of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Indentification No.)
|
| |
|
|
|
|
180
Mt. Airy Road, Suite 102
Basking
Ridge, NJ 07920
(Address
of principal executive offices)
(908)
766-4400
(Registrant's
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement
communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
5.02
|
Departure
of Directors or Principal Officers; Election of Directors; Appointment
of
Principal Officers; Compensatory Arrangements of Certain
Officers
|
VioQuest
Pharmaceuticals, Inc. (the “Company”) previously reported in its Current Report
on Form 8-K filed on April 15, 2008 that Edward C. Bradley, M.D., the Company’s
former Chief Scientific Officer, had resigned from his part-time position on
April 11, 2008. Upon commencement of his employment with the Company, Dr.
Bradley had received stock options to purchase 700,000 shares of the Company’s
common stock. The terms of his employment agreement provided that stock options
representing 233,333 shares of the Company’s common stock vested on February 1,
2008, with the balance of the stock options to vest in equal installments on
February 1, 2009 and 2010. On April 15, 2008, the Company agreed to immediately
vest an additional 233,333 shares subject to Dr. Bradley’s stock options, so
that as of April 15, 2008, Dr. Bradley’s right to purchase an aggregate of
466,666 shares subject to his stock option is vested and exercisable. The
Company also extended the exercise period with respect to Dr. Bradley’s options
until December 31, 2008. The Company has no other obligations to pay Dr. Bradley
any further compensation.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
|
|
| |
VioQuest
Pharmaceuticals, Inc. |
|
|
|
| Date: April
21, 2008 |
By: |
/s/ Brian
Lenz |
| |
Brian
Lenz |
| |
Title:
Chief
Financial Officer |